Presentation is loading. Please wait.

Presentation is loading. Please wait.

ASCO 2018 Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment Published: Thursday, Jun 14, ESTUDOS DE FASE I: TUCATINIBE + TRASTUZUMABE +

Published byLuciana Zapata Modified over 5 years ago

Similar presentations

Presentation on theme: "ASCO 2018 Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment Published: Thursday, Jun 14, ESTUDOS DE FASE I: TUCATINIBE + TRASTUZUMABE +"— Presentation transcript:

1 ASCO 2018 Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment Published: Thursday, Jun 14, 2018 02 ESTUDOS DE FASE I: TUCATINIBE + TRASTUZUMABE + CAPECITABINA TUCATINIBE + T-DM1

Download ppt "ASCO 2018 Tracing Tucatinib's Role in HER2+ Breast Cancer Treatment Published: Thursday, Jun 14, ESTUDOS DE FASE I: TUCATINIBE + TRASTUZUMABE +"

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Miles D et al. Proc SABCS 2012;Abstract P
Dr Antonio C. Buzaid Chefe Geral Centro Avançado de Oncologia

Dr Antonio C. Buzaid Chefe Geral Centro Avançado de Oncologia
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
1/03/09 De 89 à 98. 1/03/09 De 89 à 98 1/03/09 De 89 à 98.

1/03/09 De 89 à 98. 1/03/09 De 89 à 98 1/03/09 De 89 à 98.
Herceptin. The Scientific name is Trastuzumab and Herciptin is the Commercial name.

Herceptin. The Scientific name is Trastuzumab and Herciptin is the Commercial name.
Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With.

Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With.
Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.

Geonomics in Breast Cancer Decoding Human Genome Luis Barreras, M.D., FACP.
Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
75777981 81797775 83858789 89878583 91939597 97959391.

Activity: #6 Case Study.  Janet Jacobson is 45 years old and went in for her routine mammogram.  The mammogram showed a questionable area in her breast.

Activity: #6 Case Study.  Janet Jacobson is 45 years old and went in for her routine mammogram.  The mammogram showed a questionable area in her breast.
Objectives Discuss the history of breast cancer. Describe the pathology of breast cancer and list significant tumor markers. Differentiate IHC testing.

Objectives Discuss the history of breast cancer. Describe the pathology of breast cancer and list significant tumor markers. Differentiate IHC testing.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Www.OncologyEducation.com ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.

ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.
Ovarian Cancer I D ARTHUR, FRCOG. DM. March 2012.

Ovarian Cancer I D ARTHUR, FRCOG. DM. March 2012.
Social Roles and Relationships.

Social Roles and Relationships.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Gerber, B; Marx, M; Untch, M; Faridi, A Breast Reconstruction Following Cancer Treatment Dtsch Arztebl Int 2015; 112(35-36): 593-600; DOI: 10.3238/arztebl.2015.0593.

Gerber, B; Marx, M; Untch, M; Faridi, A Breast Reconstruction Following Cancer Treatment Dtsch Arztebl Int 2015; 112(35-36): ; DOI: /arztebl
Activity: Case Study Cancer.  Janet Jacobson is 45 years old and went in for her routine mammogram.  The mammogram showed a questionable area in her.

Activity: Case Study Cancer.  Janet Jacobson is 45 years old and went in for her routine mammogram.  The mammogram showed a questionable area in her.
Breast cancer facts Daniela Cazares. Fact #1 In the US, 1 in 8 women will be diagnosed with breast cancer in their lifetime.

Breast cancer facts Daniela Cazares. Fact #1 In the US, 1 in 8 women will be diagnosed with breast cancer in their lifetime.

Similar presentations

Ads by Google